Core Insights - Immuron Limited has entered a research collaboration with Monash University to develop new therapeutic drug candidates targeting antimicrobial resistant pathogens [1][2] - The collaboration will utilize Immuron's technology platform and the expertise of the Biomedicine Discovery Institute led by Professor Dena Lyras [2] - The initial activities of the collaboration will not require additional funding beyond Immuron's existing research budget [3] Project Proposals - The first project will investigate the mechanisms by which bacteria share and transfer DNA, contributing to antimicrobial resistance, with the goal of developing broad-spectrum therapeutic products [5] - The second project will focus on Vancomycin-resistant enterococci (VRE), which are significant nosocomial pathogens that complicate treatment outcomes for vulnerable patients [7] Market Context - Antimicrobial resistance (AMR) is a major global health threat, leading to severe infections and increased healthcare costs, with the U.S. alone spending over $4.6 billion annually to treat such infections [6] - The global antibiotics market is projected to reach $57.0 billion by 2026, growing at a compound annual growth rate (CAGR) of 4.0%, driven by the rising prevalence of drug-resistant infections [8]
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance